Does Humana Cover AndroGel? Formulary, Prior Auth, Step Therapy, and Appeals

What AndroGel Is and Why Coverage Rules Are Complicated

AndroGel is a topical testosterone gel approved by the FDA in two concentrations, 1% (approved 2000) and 1.62% (approved 2011), for adult males with primary or hypogonadotropic hypogonadism [1]. Because testosterone is a Schedule III controlled substance under the Controlled Substances Act, every prescription carries extra administrative layers regardless of insurer. Humana must also comply with Centers for Medicare and Medicaid Services (CMS) rules for its Medicare Advantage products, which creates a two-tier coverage reality: commercial members face moderate prior authorization hurdles, while MA members may face outright exclusion.

The FDA-approved prescribing information for AndroGel 1.62% lists the indication as replacement therapy in males with conditions associated with a deficiency or absence of endogenous testosterone [1]. That language matters to Humana's utilization management team, because any claim submitted with a diagnosis code outside that narrow window, age-related decline without lab confirmation, for example, will likely trigger an automatic denial.

The T-Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older with total testosterone <275 ng/dL, found that testosterone treatment for one year improved sexual function scores and modestly increased bone density, but produced mixed results on physical function and energy [2]. That evidence base shapes Endocrine Society clinical practice guidelines, which Humana's medical-policy writers routinely reference when setting prior authorization criteria [3].

Humana Commercial Formulary: What Tier Is AndroGel?

Most Humana commercial formularies place AndroGel on Tier 3 (non-preferred brand) or Tier 4 (preferred specialty), depending on the specific plan year and employer contract. Tier placement determines your copay structure before deductible and after it.

On a typical Humana Tier 3 plan, a 30-day supply of AndroGel 1.62% carries a copay of $60 to $100 after deductible under in-network pharmacy benefits. Tier 4 specialty placement can push that figure to $150 or higher, and some high-deductible health plans require you to meet a $1,500 to $3,000 individual deductible before any cost-sharing applies. The exact tier for your specific plan is searchable through Humana's online drug-lookup tool or by calling the member services number on your insurance card.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends treatment only when patients have "unequivocally low serum testosterone concentrations and signs and symptoms of androgen deficiency" [3]. Humana's commercial PA criteria mirror that language closely, generally requiring two fasting morning total testosterone values <300 ng/dL drawn at least one week apart, plus documented symptoms such as reduced libido, fatigue, or loss of muscle mass.

Generic testosterone products, testosterone cypionate injection (200 mg/mL) and testosterone enanthate injection, carry Tier 1 or Tier 2 placement on most Humana formularies [4]. That discrepancy is the direct reason most Humana commercial plans impose step therapy before approving a brand-name gel.

Prior Authorization Criteria for AndroGel on Humana

Prior authorization (PA) for AndroGel on Humana commercial plans is classified as moderate difficulty. The clinical review team evaluates documentation across four core domains.

Confirmed diagnosis. The chart must show a diagnostic code for primary hypogonadism (ICD-10 E29.1) or hypogonadotropic hypogonadism (E23.0). Age-related decline coded as E34.9 or Z00.00 is frequently denied without additional supporting lab data.

Lab confirmation. Two total testosterone values <300 ng/dL drawn on separate mornings before 10 a.m. are the most common threshold. Some Humana PA forms also request a simultaneous LH and FSH panel to differentiate primary from secondary hypogonadism, because that distinction affects whether the patient qualifies for additional treatment options [3].

Symptom documentation. The prescribing physician must provide a signed attestation or office-visit note documenting at least two of the following: decreased libido, erectile dysfunction, fatigue, depressed mood, decreased lean body mass, or reduced bone density. The FDA label for AndroGel reinforces this requirement by restricting use to patients with "a clinical condition associated with a deficiency" [1].

Step therapy completion or exemption. See the dedicated section below for full detail, but in brief, Humana requires a documented 90-day trial of testosterone cypionate injection 200 mg/mL every two weeks (or equivalent) unless the prescriber documents a specific medical contraindication to injections, such as a bleeding disorder or needle phobia with psychological documentation.

PA approvals are typically valid for 12 months. Annual renewal requires repeat testosterone labs confirming continued deficiency and a brief note documenting ongoing symptom management. The Humana PA submission portal accepts electronic submissions via CoverMyMeds, and most decisions are returned within 72 business hours for standard requests or 24 hours for urgent clinical situations.

Step Therapy Requirements Before AndroGel

Step therapy is the main access barrier for most commercially insured Humana members seeking AndroGel specifically. The step protocol requires trying one preferred testosterone formulation first.

Humana's preferred first-line agents include testosterone cypionate injection (generic, Tier 1) and, on some plans, testosterone enanthate injection (generic, Tier 1) [4]. A required trial period of 60 to 90 days is standard. If the patient experiences inadequate clinical response, meaning testosterone levels remain <300 ng/dL at trough, or documented symptom persistence, or if the patient has a documented intolerance such as injection-site hematoma, worsening polycythemia, or severe injection anxiety, the prescriber can submit step-therapy override documentation to move directly to the gel.

The American Urological Association's 2018 guideline on testosterone deficiency states that route of administration should be individualized based on patient preference, tolerability, and pharmacokinetic factors [5]. That guideline language gives prescribers a legitimate clinical rationale for requesting a step-therapy exception when injections are genuinely unsuitable.

The HealthRX clinical team uses a four-point step-therapy override checklist when preparing Humana PA packages for AndroGel:

1. Documented allergy or intolerance to injection vehicle (cottonseed or sesame oil).
2. Active anticoagulation therapy (warfarin, apixaban) where intramuscular injections carry documented bleeding risk.
3. Psychological contraindication with a licensed mental health provider note on file.
4. Prior injection trial with lab-confirmed failure to achieve therapeutic trough levels (>400 ng/dL at 14-day trough for cypionate 200 mg every two weeks).

Presenting all four data points in a single PA package reduces the back-and-forth with Humana's pharmacy team and cuts average approval time.

Humana Medicare Advantage Coverage of AndroGel

Medicare Advantage coverage of AndroGel is substantially more complicated than commercial coverage. CMS does not categorically prohibit testosterone coverage in MA plans, but CMS guidance restricts MA formularies from covering drugs used primarily for anabolic or anti-aging purposes [6]. Many Humana MA plans exclude testosterone gels entirely or require non-standard PA criteria that are harder to satisfy.

For MA members, the typical PA pathway requires:

• Primary or secondary hypogonadism confirmed by two morning testosterone values <300 ng/dL.
• Specialist confirmation from a board-certified endocrinologist or urologist.
• Documentation that the condition is not age-related decline alone.
• For continuation PA, a repeat testosterone level drawn at trough demonstrating response.

When a Humana MA plan denies AndroGel, the denial letter must include the specific clinical rationale and the enrollee's right to appeal within 60 days. The internal reconsideration process at Humana must be completed within 30 days for standard cases or 72 hours for expedited medical necessity requests [7]. If Humana upholds the denial, the case moves to MAXIMUS Federal Services, the independent review entity contracted by CMS for Medicare-specific external appeals [7].

A 2020 analysis published in JAMA Internal Medicine found that approximately 75% of Medicare Advantage coverage denials that proceeded to external review were ultimately overturned, suggesting that persistence through the appeals process produces meaningful results [8]. That statistic applies to all drug denials, not testosterone specifically, but it underscores the value of completing the full appeal chain rather than abandoning after an initial denial.

How to Appeal a Humana Denial of AndroGel

A denial is not a final answer. The appeals process has defined statutory timelines and a structured sequence.

Step 1: Request a Redetermination (Commercial) or Reconsideration (MA). Submit a written request within 60 days of the denial notice. Attach the prescribing physician's clinical letter, both lab reports with collection timestamps, and any specialist notes. For commercial plans, Humana's grievance and appeals team handles this internally. For MA plans, Humana's MA appeals department processes the reconsideration, and the standard timeline is 30 calendar days (7 days for expedited).

Step 2: Independent Review / IRE. If Humana upholds the denial at the reconsideration level, MA members escalate to MAXIMUS Federal, the CMS-contracted independent review entity [7]. Commercial members file with an independent external review organization designated by their state insurance commissioner. IRE decisions are binding on the plan.

Step 3: Administrative Law Judge Hearing. For MA members whose claim value meets the minimum threshold (currently $180 for 2024), a hearing before an ALJ is available within 60 days of an unfavorable IRE decision.

Step 4: Medicare Appeals Council, then Federal District Court. These final steps are rarely needed but are available for claims meeting the dollar threshold.

The most common reason appeals succeed is stronger documentation, not new clinical arguments. A letter from a board-certified endocrinologist citing the T-Trials [2] and the Endocrine Society guideline's specific serum threshold language [3] carries substantially more weight than a brief physician attestation. The FDA's prescribing information for AndroGel, which explicitly defines the approved indication, is also a valid document to attach to any appeal package [1].

AndroGel Cost Without Humana Coverage and Savings Options

The average wholesale price for AndroGel 1.62% (75 g pump, 30-day supply at 40.5 mg/day) runs approximately $510 per month. GoodRx and similar discount programs can reduce that to roughly $280 to $320 at certain retail pharmacies, though prices vary by zip code.

AbbVie, the manufacturer of AndroGel, offers the AndroGel Savings Card for commercially insured patients. Eligible patients may pay as little as $0 per month for up to 12 fills, subject to program terms and income eligibility. The savings card cannot be used by patients enrolled in Medicare, Medicaid, CHIP, TRICARE, or any other federal or state health care program [9]. Using the card while enrolled in a federal program constitutes a violation of program terms and potentially federal law.

Compounded testosterone gel (typically 2% or 10% strength prepared by a 503A compounding pharmacy) may be available for $50 to $80 per month and does not require the same insurer prior authorization process, because it is not a covered drug under most formularies. The FDA has noted that compounded testosterone products are not FDA-approved and lack the bioavailability data of the branded product [10]. Physicians who prescribe compounded testosterone for patients transitioning off formulary coverage should document their clinical rationale clearly.

Testosterone cypionate injection 200 mg/mL (10 mL vial) is available at most major pharmacies for $30 to $50 per month on GoodRx pricing, reinforcing why step therapy protocols push injections first.

Does Humana Cover AndroGel for Weight Loss?

No. AndroGel is not FDA-approved for weight loss, and Humana will not approve a PA for testosterone gel submitted with a primary diagnosis of obesity or weight management. The FDA label restricts use to replacement therapy in males with classical hypogonadism [1].

Some clinicians have observed that testosterone therapy in men with true hypogonadism can produce modest reductions in fat mass as a secondary effect. A meta-analysis of 58 randomized trials (N=3,236) published in the Journal of Clinical Endocrinology and Metabolism found that testosterone therapy reduced fat mass by a mean of 1.6 kg compared with placebo over 6 to 12 months [11]. That finding relates to a secondary metabolic effect in hypogonadal men, not a primary weight-loss indication. Submitting a PA with obesity as the primary diagnosis will result in automatic denial.

Lab Values and Documentation That Strengthen a Humana PA

Timing and completeness of lab documentation are the two most common PA failure points. Labs drawn after 10 a.m. show physiological testosterone decline and may not reflect true basal levels, which can cause Humana reviewers to request a repeat draw. Both samples must be collected between 7 a.m. and 10 a.m. in a fasted state.

Beyond total testosterone, adding free testosterone and sex-hormone-binding globulin (SHBG) to the lab panel strengthens the clinical picture. Men with high SHBG may have normal total testosterone but low free testosterone (<65 pg/mL), a pattern recognized in the Endocrine Society's 2018 guideline as a valid indication for treatment when accompanied by symptoms [3]. Humana's PA reviewers may accept free testosterone data as supplementary evidence when total testosterone sits in the borderline 300 to 350 ng/dL range.

A complete PA package for Humana should include: the office note from the initial diagnosis visit, both testosterone lab reports with collection time stamps, LH and FSH results, a completed Humana PA request form (obtainable through CoverMyMeds or Humana's provider portal), and a physician attestation letter referencing the FDA-approved indication language.

The Endocrine Society's 2018 guideline states, "We suggest that clinicians measure morning total testosterone level using a reliable assay as the initial test," and further recommends confirmatory testing with a second sample before initiating therapy [3]. Quoting that specific guideline recommendation in the PA letter gives Humana's clinical reviewer a clear, citable anchor for approval.

Generic Testosterone Alternatives on the Humana Formulary

If AndroGel is denied or unaffordable, several formulary-preferred alternatives exist.

Testosterone cypionate injection (generic) is Tier 1 on most Humana plans at roughly $10 to $20 per month with Humana cost-sharing. Self-administered intramuscular injections every 7 to 14 days provide steady pharmacokinetics when dose is individualized. A 2017 review in Therapeutic Advances in Urology confirmed that testosterone cypionate and enanthate produce equivalent steady-state serum levels when dosed every 14 days at 200 mg [12].

Testosterone enanthate injection (generic) is similarly Tier 1 and interchangeable with cypionate for most clinical purposes.

Axiron (testosterone solution, 2%) and Fortesta (testosterone gel 2%) are brand alternatives to AndroGel that may sit on different formulary tiers on specific Humana plans. Testim (testosterone gel 1%) is another option. Checking the specific plan formulary for the current benefit year is the only way to confirm tier placement, because Humana updates formularies on January 1 each year and may issue mid-year exceptions.

Natesto (testosterone nasal gel, 4.5 mg per actuation) is a newer delivery option that may be preferred for men concerned about transference to partners or children, a documented safety issue the FDA flagged in a 2009 black-box warning added to all topical testosterone products [1]. Natesto sits on Tier 3 or Tier 4 on most Humana plans and generally requires its own PA.